Tacedinaline | CI-944 | CAS#112522-64-2 | HDAC Inhibitor

MedKoo Cat#: 205997 | Name: Tacedinaline

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Tacedinaline, also known as CI-944 and PD123654, is a n orally bioavailable substituted benzamide derivative with potential antineoplastic activity. Tacedinaline inhibits histone deacetylation, which may result in histone hyperacetylation, followed by the induction of differentiation, the inhibition of cell proliferation, and apoptosis in susceptible tumor cell populations.

Chemical Structure

Tacedinaline

CAS#112522-64-2

Theoretical Analysis

MedKoo Cat#: 205997

Name: Tacedinaline

CAS#: 112522-64-2

Chemical Formula: C15H15N3O2

Exact Mass: 269.1164

Molecular Weight: 269.30

Elemental Analysis: C, 66.90; H, 5.61; N, 15.60; O, 11.88

Price and Availability

Size	Price	Availability
50mg	USD 350.00	2 Weeks
100mg	USD 650.00	2 Weeks
200mg	USD 950.00	2 Weeks
500mg	USD 1,250.00	2 Weeks
1g	USD 1,950.00	2 Weeks
2g	USD 2,950.00	2 Weeks
5g	USD 4,650.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

CI994; CI-994; CI 994; PD123654; PD-123654; PD 123654; Tacedinaline; Acetyldinaline; N-Acetyldinaline; Goe 5549; Goe5549; Goe-5549;

IUPAC/Chemical Name

4-acetamido-N-(2-aminophenyl)benzamide

InChi Key

VAZAPHZUAVEOMC-UHFFFAOYSA-N

InChi Code

InChI=1S/C15H15N3O2/c1-10(19)17-12-8-6-11(7-9-12)15(20)18-14-5-3-2-4-13(14)16/h2-9H,16H2,1H3,(H,17,19)(H,18,20)

SMILES Code

O=C(NC1=CC=CC=C1N)C2=CC=C(NC(C)=O)C=C2

Appearance

Off-white solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>5 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 269.30 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Berluti F, Baselious F, Hagemann S, Hilscher S, Schmidt M, Hüttelmaier S, Schutkowski M, Sippl W, Ibrahim HS. Development of new pyrazoles as class I HDAC inhibitors: Synthesis, molecular modeling, and biological characterization in leukemia cells. Arch Pharm (Weinheim). 2024 Nov;357(11):e2400437. doi: 10.1002/ardp.202400437. Epub 2024 Sep 18. PMID: 39291901. 2: Carnalla M, López-Olmedo N, Ramírez-Toscano Y, Cárdenas-Cárdenas LM, Canto- Osorio F, Rengifo-Reina H, Barrera-Núñez D, Quiroz-Reyes JA, Colchero MA, Barrientos-Gutiérrez T. Binge drinking associated with mean temperature: a cross-sectional study among Mexican adults living in cities. Global Health. 2024 Apr 12;20(1):29. doi: 10.1186/s12992-024-01033-z. PMID: 38609988; PMCID: PMC11010420. 3: Ismail A, Chabbouh A, Charro E, El Masri J, Ghazi M, Sadier NS, Abou-Abbas L. Examining the validity and reliability of the Arabic translated version of the depression and somatic symptoms scale (A-DSSS) among the Lebanese adults. Sci Rep. 2024 Mar 5;14(1):5435. doi: 10.1038/s41598-024-55813-z. PMID: 38443403; PMCID: PMC10914820. 4: Huang W, Wang C, Wang Y, Yu Z, Wang S, Yang J, Lu S, Zhou C, Wu E, Chen J. Predicting malnutrition in gastric cancer patients using computed tomography(CT) deep learning features and clinical data. Clin Nutr. 2024 Mar;43(3):881-891. doi: 10.1016/j.clnu.2024.02.005. Epub 2024 Feb 6. PMID: 38377634. 5: Guo Z, Wang N, He X, Shen J, Yang X, Xie C, Fan Q, Zhou W. Self-amplified activatable nanophotosensitizers for HIF-1α inhibition-enhanced photodynamic therapy. Nanoscale. 2024 Feb 22;16(8):4239-4248. doi: 10.1039/d3nr05245a. PMID: 38348473. 6: Klomp MJ, van den Brink L, van Koetsveld PM, de Ridder CMA, Stuurman DC, Löwik CWGM, Hofland LJ, Dalm SU. Applying HDACis to increase SSTR2 expression and radiolabeled DOTA-TATE uptake: from cells to mice. Life Sci. 2023 Dec 1;334:122173. doi: 10.1016/j.lfs.2023.122173. Epub 2023 Oct 29. PMID: 37907154. 7: Kim CH, Chung MJ, Cha YK, Oh S, Kim KG, Yoo H. The impact of deep learning reconstruction in low dose computed tomography on the evaluation of interstitial lung disease. PLoS One. 2023 Sep 27;18(9):e0291745. doi: 10.1371/journal.pone.0291745. PMID: 37756357; PMCID: PMC10529569. 8: Zhao D, Ren K, Lu J, Liu Z, Li Z, Wu J, Xu Z, Wu S, Lei T, Ma C, Zhao S, Bai M, Li H, Guo J. Rituximab at lower dose for neuromyelitis optica spectrum disorder: a multicenter, open-label, self-controlled, prospective follow-up study. Front Immunol. 2023 Aug 8;14:1148632. doi: 10.3389/fimmu.2023.1148632. PMID: 37614240; PMCID: PMC10442836. 9: Marinho D, Ferreira IL, Lorenzoni R, Cardoso SM, Santana I, Rego AC. Reduction of class I histone deacetylases ameliorates ER-mitochondria cross-talk in Alzheimer's disease. Aging Cell. 2023 Aug;22(8):e13895. doi: 10.1111/acel.13895. Epub 2023 Jun 26. PMID: 37358017; PMCID: PMC10410063. 10: Marquardt V, Theruvath J, Pauck D, Picard D, Qin N, Blümel L, Maue M, Bartl J, Ahmadov U, Langini M, Meyer FD, Cole A, Cruz-Cruz J, Graef CM, Wölfl M, Milde T, Witt O, Erdreich-Epstein A, Leprivier G, Kahlert U, Stefanski A, Stühler K, Keir ST, Bigner DD, Hauer J, Beez T, Knobbe-Thomsen CB, Fischer U, Felsberg J, Hansen FK, Vibhakar R, Venkatraman S, Cheshier SH, Reifenberger G, Borkhardt A, Kurz T, Remke M, Mitra S. Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation. J Immunother Cancer. 2023 Jan;11(1):e005871. doi: 10.1136/jitc-2022-005871. PMID: 36639156; PMCID: PMC9843227. 11: Zemskov EA, Gross CM, Aggarwal S, Zemskova MA, Wu X, Gu C, Wang T, Tang H, Black SM. NF-κB-dependent repression of Sox18 transcription factor requires the epigenetic regulators histone deacetylases 1 and 2 in acute lung injury. Front Physiol. 2022 Aug 4;13:947537. doi: 10.3389/fphys.2022.947537. PMID: 35991176; PMCID: PMC9386230. 12: Burns AM, Farinelli-Scharly M, Hugues-Ascery S, Sanchez-Mut JV, Santoni G, Gräff J. The HDAC inhibitor CI-994 acts as a molecular memory aid by facilitating synaptic and intracellular communication after learning. Proc Natl Acad Sci U S A. 2022 May 31;119(22):e2116797119. doi: 10.1073/pnas.2116797119. Epub 2022 May 25. PMID: 35613054; PMCID: PMC9295763. 13: Schäker-Hübner L, Haschemi R, Büch T, Kraft FB, Brumme B, Schöler A, Jenke R, Meiler J, Aigner A, Bendas G, Hansen FK. Balancing Histone Deacetylase (HDAC) Inhibition and Drug-likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors. ChemMedChem. 2022 May 4;17(9):e202100755. doi: 10.1002/cmdc.202100755. Epub 2022 Feb 18. PMID: 35073610; PMCID: PMC9303312. 14: Lin HY, Wu HJ, Chen SY, Hou MF, Lin CS, Chu PY. Epigenetic therapy combination of UNC0638 and CI-994 suppresses breast cancer via epigenetic remodeling of BIRC5 and GADD45A. Biomed Pharmacother. 2022 Jan;145:112431. doi: 10.1016/j.biopha.2021.112431. Epub 2021 Nov 16. PMID: 34798471. 15: McClarty B, Rodriguez G, Dong H. Dose Effects of Histone Deacetylase Inhibitor Tacedinaline (CI-994) on Antipsychotic Haloperidol-Induced Motor and Memory Side Effects in Aged Mice. Front Neurosci. 2021 Oct 6;15:674745. doi: 10.3389/fnins.2021.674745. PMID: 34690667; PMCID: PMC8526546. 16: Sirous H, Campiani G, Calderone V, Brogi S. Discovery of novel hit compounds as potential HDAC1 inhibitors: The case of ligand- and structure-based virtual screening. Comput Biol Med. 2021 Oct;137:104808. doi: 10.1016/j.compbiomed.2021.104808. Epub 2021 Aug 26. PMID: 34478925. 17: Ulanova AD, Gritsyna YV, Bobylev AG, Yakupova EI, Zhalimov VK, Belova SP, Mochalova EP, Nemirovskaya TL, Shenkman BS, Vikhlyantsev IM. Inhibition of Histone Deacetylase 1 Prevents the Decrease in Titin (Connectin) Content and Development of Atrophy in Rat m. soleus after 3-Day Hindlimb Unloading. Bull Exp Biol Med. 2020 Aug;169(4):450-457. doi: 10.1007/s10517-020-04907-5. Epub 2020 Sep 5. PMID: 32889570. 18: Sada N, Fujita Y, Mizuta N, Ueno M, Furukawa T, Yamashita T. Inhibition of HDAC increases BDNF expression and promotes neuronal rewiring and functional recovery after brain injury. Cell Death Dis. 2020 Aug 18;11(8):655. doi: 10.1038/s41419-020-02897-w. PMID: 32811822; PMCID: PMC7434917. 19: Shepard RD, Langlois LD, Authement ME, Nugent FS. Histone deacetylase inhibition reduces ventral tegmental area dopamine neuronal hyperexcitability involving AKAP150 signaling following maternal deprivation in juvenile male rats. J Neurosci Res. 2020 Jul;98(7):1457-1467. doi: 10.1002/jnr.24613. Epub 2020 Mar 11. PMID: 32162391; PMCID: PMC7242123. 20: Cooper A, Butto T, Hammer N, Jagannath S, Fend-Guella DL, Akhtar J, Radyushkin K, Lesage F, Winter J, Strand S, Roeper J, Zechner U, Schweiger S. Inhibition of histone deacetylation rescues phenotype in a mouse model of Birk- Barel intellectual disability syndrome. Nat Commun. 2020 Jan 24;11(1):480. doi: 10.1038/s41467-019-13918-4. PMID: 31980599; PMCID: PMC6981138.